MedTrace Logo

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

NCT06355258 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-11-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are:

* Does troxerutin lower the number of thrombotic events in participants?
* What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients.

Participants will:

* Take troxerutin or a placebo every day for 7 days.
* Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests
* Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia

Conditions

  • COVID 19 Associated Coagulopathy

Interventions

DRUG

Troxerutin

Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

DRUG

Placebo

Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

DRUG

placebo + low molecular weight heparin

2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

DRUG

troxerutin + low molecular weight heparin

2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

Sponsors & Collaborators

  • Shaoxing Central Hospital

    collaborator OTHER

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

    collaborator UNKNOWN

  • Westlake University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-15
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06355258 on ClinicalTrials.gov